Vassalotti Joseph A, Francis Anna, Soares Dos Santos Augusto Cesar, Correa-Rotter Ricardo, Abdellatif Dina, Hsiao Li-Li, Roumeliotis Stefanos, Haris Agnes, Kumaraswami Latha A, Lui Siu-Fai, Balducci Alessandro, Liakopoulos Vassilios
Clin Nephrol. 2025 Aug;104(2):87-96. doi: 10.5414/CNWKDEdi25.
Early identification of kidney disease can protect kidney health, prevent kidney disease progression and related complications, reduce cardiovascular disease risk and decrease mortality. We must ask , using serum creatinine to estimate kidney function and urine albumin to assess for kidney and endothelial damage. Evaluation for causes and risk factors for chronic kidney disease (CKD) includes testing for diabetes and measurement of blood pressure and body mass index. This World Kidney Day we assert that case-finding in high-risk populations, or even populationlevel screening, can decrease the burden of kidney disease globally. Early-stage CKD is asymptomatic, simple to test for, and recent paradigm shifting CKD treatments such as sodium glucose co-transporter-2 inhibitors dramatically improve outcomes and favor the cost-benefit analysis for screening or case-finding programs. Despite this, numerous barriers exist, including resource alloca-Editorial tion, healthcare funding, healthcare infrastructure, and healthcare-professional and population awareness of kidney disease. Coordinated efforts by major kidney nongovernmental organizations to prioritize the kidney health agenda for governments and aligning early detection efforts with other current programs will maximize efficiencies.
早期识别肾脏疾病可以保护肾脏健康，预防肾脏疾病进展及相关并发症，降低心血管疾病风险并减少死亡率。我们必须思考，利用血清肌酐来评估肾功能以及利用尿白蛋白来评估肾脏和内皮损伤。对慢性肾脏病（CKD）病因及风险因素的评估包括检测糖尿病以及测量血压和体重指数。在今年的世界肾脏日，我们断言，在高危人群中进行病例发现，甚至进行人群层面的筛查，可以减轻全球肾脏疾病的负担。早期CKD没有症状，检测简单，并且近期如钠-葡萄糖协同转运蛋白2抑制剂等改变CKD治疗模式的药物显著改善了治疗效果，有利于筛查或病例发现项目的成本效益分析。尽管如此，仍存在众多障碍，包括资源分配、医疗保健资金、医疗保健基础设施以及医疗保健专业人员和公众对肾脏疾病的认知。主要肾脏非政府组织通过协调努力，为各国政府确定肾脏健康议程的优先事项，并使早期检测工作与其他现有项目保持一致，将实现效率最大化。
